Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Chief Commercial Ofc Imm Med | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 06/26–06/29 | 06/30 | 165,802 sh2 trades | $21.13avg. | $3,503,509.52 | −42.8% |
Michelle Renee GriffinDirector | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 06/25 | 06/29 | 52,084 sh | $20.18 | $1,051,055.12 | −76.9% |
Susan BobulskyChief Commercial Officer, MRD | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 06/25 | 06/29 | 5,000 sh | $20.50 | $102,500 | −1.2% |
Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 06/15–06/16 | 06/17 | 106,160 sh2 trades | $17.41avg. | $1,847,941.6 | −7.0% | |
Susan BobulskyChief Commercial Officer, MRD | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 06/11 | 06/15 | 5,000 sh | $19.00 | $95,000 | −1.2% |
Francis LoChief People Officer | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 06/04 | 06/08 | 39,741 sh | $17.49 | $695,070.09 | −13.7% |
Susan BobulskyChief Commercial Officer, MRD | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 06/04 | 06/08 | 11,000 sh | $18.00 | $198,000 | −2.6% |
Kyle PiskelCFO | Adaptive BiotechnologiesADPT | Open-market sale | 05/18 | 05/20 | 3,115 sh | $13.04 | $40,619.6 | −1.2% |
Julie RubinsteinPresident and COO | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 04/27 | 04/29 | 19,037 sh | $14.23 | $270,896.51 | −4.8% |
President and COO | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 04/22–04/24 | 04/24 | 57,180 sh3 trades | $13.96avg. | $798,423.4 | −13.0% |
President and COO | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 04/17–04/21 | 04/21 | 69,061 sh3 trades | $14.60avg. | $1,008,622.26 | −14.9% |
President and COO | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 04/14–04/16 | 04/16 | 57,180 sh3 trades | $14.45avg. | $826,251 | −12.3% |
President and COO | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 04/09–04/13 | 04/13 | 57,180 sh6 trades | $13.26avg. | $758,108.34 | −12.0% |
Francis LoChief People Officer | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 04/08 | 04/10 | 22,564 sh | $15.07 | $340,039.48 | −7.7% |
Harlan S. RobinsChief Scientific Officer | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 04/08 | 04/10 | 10,000 sh | $14.85 | $148,500 | −0.7% |
CEO and Chairman | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 04/06–04/08 | 04/08 | 120,595 sh2 trades | $14.65avg. | $1,766,839.09 | −5.2% |
President and COO | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 04/06–04/08 | 04/08 | 69,061 sh4 trades | $14.34avg. | $990,503.43 | −13.7% |
President and COO | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 04/01–04/02 | 04/02 | 38,120 sh2 trades | $14.53avg. | $553,693 | −7.9% |
President and COO | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 03/27–03/31 | 03/31 | 57,180 sh4 trades | $13.14avg. | $751,302.98 | −11.1% |
President and COO | Adaptive BiotechnologiesADPT | Open-market sale10b5-1 plan | 03/24–03/26 | 03/26 | 57,180 sh3 trades | $14.03avg. | $802,235.4 | −10.9% |
